Aligos Therapeutics, Inc. (ALGS) · Nov 6, 2026 · Earnings
Miss — Revenue $2.87M vs ~$4.85M consensus
Aligos earnings beat loss estimates on lower costs, but revenue missed consensus and cash now funds operations only into Q1 2027.
Aligos remains a clinical-stage HBV biotech whose lead asset, pevifoscorvir sodium, is in Phase 2 with enrollment complete and topline data targeted for late Q3 2027; that timetable and the study’s enrollment milestone were already disclosed earlier this year.
The trial story is progressing, but this filing adds little new efficacy information. Aligos says 245 participants are enrolled across the two B-SUPREME cohorts and that topline data remain expected in late Q3 2027, while 70 participants have completed 48 weeks of treatment. The key milestone is therefore execution against an established plan, not a clinical readout.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Revenue (Financial Results) | $2.87M (-56.5% vs. consensus) | $0.74M | $4.85M |
| Net loss (Financial Results) | $21.86M | $31.54M | |
| Diluted EPS (Financial Results) | $(2.09) | $(3.04) | $(2.28)–$(2.44) |
| R&D expense (Financial Results) | $18.89M (-21.1%) | $23.94M | |
| Cash, equivalents and investments (Financial Results) | $31.1M | $77.8M |
The headline earnings signal is mixed, but the revenue miss is the cleaner benchmark. Quarterly revenue of $2.87 million was well below the published consensus near $4.85 million, even though the per-share loss was narrower than estimates around $2.28–$2.44. The EPS improvement was helped by lower R&D spending and a favorable warrant fair-value swing, rather than by a stronger operating revenue base. Aligos reported R&D expense of $18.9 million versus $23.9 million a year earlier.
Liquidity remains the main business constraint. Cash, equivalents and investments fell to $31.1 million from $77.8 million at year-end, and management says cash and cash equivalents fund planned operations only into the first quarter of 2027. Earlier 2026 filings had already indicated a need for additional capital beyond late 2026, so this filing confirms rather than resolves the financing problem.
Bottom line: Aligos is executing on its lead HBV trial, but the update does not materially improve the clinical story and leaves a large revenue miss alongside a near-term funding need. The narrower loss is not enough to offset that underlying pressure.
Financing or cash update before Q1 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!